Gujarat Themis Biosyn Limited

100%

he Investors’ Presentation of the Gujarat Themis Biosyn Limited (‘the Company’) for acquisition of 100% equity shareholding in MicroBiopharm Japan Co., Ltd. (“MBJ”), Japan, through Themis Biosyn Japan L

21.5 Billion

ed or advised by T Capital Partners Co., Ltd. (Japan-based Private Equity Fund) Consideration JPY 21.5 Billion/Bn (~INR 1,300 Crore/Cr); funded through an optimal mix of debt and equity. Transaction expected to

INR 1,300 Crore

Capital Partners Co., Ltd. (Japan-based Private Equity Fund) Consideration JPY 21.5 Billion/Bn (~INR 1,300 Crore/Cr); funded through an optimal mix of debt and equity. Transaction expected to be EPS accretive M

19%

crobiopharm Japan Co., Ltd. 60+ Years of Experience Developed Pharmaceuticals (bio)/Non-Pharma 19% CDMO Bio 12% FY 26E 3 Plants GMP-Compliant, with FDA & PMDA Approval Track Record JPY 9.5 Bn

12%

pan Co., Ltd. 60+ Years of Experience Developed Pharmaceuticals (bio)/Non-Pharma 19% CDMO Bio 12% FY 26E 3 Plants GMP-Compliant, with FDA & PMDA Approval Track Record JPY 9.5 Bn (INR ~570 Cr)

32%

9.5 Bn (INR ~570 Cr) FY 26E Revenue Business Mix KEY STRENGTHS Proprietary - API/Intermediates 32% CDMO 37% Fermentation Bacterial culture, microbial fermentation, large scale fermentation, Preci

37%

NR ~570 Cr) FY 26E Revenue Business Mix KEY STRENGTHS Proprietary - API/Intermediates 32% CDMO 37% Fermentation Bacterial culture, microbial fermentation, large scale fermentation, Precision Ferm

40%

, Precision Fermentation Customer Relationships Servicing Top 6 customers for over two decades* 40% revenue from outside of Japan Novel Technology Platforms Plasmid DNA, ADC Conjugation , Strain &

“There can be no assurance that the transaction will be completed on the terms described or at all.”

Email

2

Web

2

Sub

1

Sub

Investor Presentation In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we submit herewith the Investors’ Presentation of the Gujarat Themis Biosyn Limited (‘the Company’) for acquisition of 100% equity shareholding in MicroBiopharm Japan Co., Ltd. (“MBJ”), Japan, through Themis Biosyn Japan Limited, a wholly owned Subsidiary incorporated in Japan. Further, a copy of the same is also available on the website of the Company, viz., www.gtbl.in Kindly take the same on record and acknowledge receipt of the same. Thanking you, Yours faithfully, For Gujarat Themis Biosyn Limited Dinesh S. Patel Chairman & Director DIN: 00033273 MUMBAI OFFICE: Themis House, 11/12 Udyog Nagar, S.V Road, Goregaon (West), Mumbai – 400 104 Tel: 91-22-67607080 / 28757836 Fax: 28746621 / 67607019; E-mail: gtblmumbai@gtbl.in Website Address: www.gtbl.in Gujarat Themis Biosyn Limited to Acquire MicroBiopharm Japan Co., Ltd. Accelerating GTBL's Tran

Web

www.adfactorspr.com Gujarat Themis Biosyn Limited Thank You Building Fermentation-based Globally Integrated CDMO Gujarat Themis Biosyn Limited | www.gtbl.in